Department of Human Anatomy, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
Orthopedics and Traumatology Service, University Hospital "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Av. Francisco I. Madero and Av. Dr. José Eleuterio González, 64460, Monterrey, Nuevo León, México.
Int Orthop. 2019 Mar;43(3):531-538. doi: 10.1007/s00264-018-4211-5. Epub 2018 Oct 27.
Osteoarthritis (OA) is one of the most common causes of disability and a prevalent chronic disease. The use of collagen is growing due to the satisfactory results in the treatment of OA. However, the possible beneficial effects of collagen for the treatment of OA are currently controversial. The aim of the present meta-analysis was to evaluate the effect of collagen-based supplements on OA symptoms.
PubMed-Medline, Scopus, and Google Scholar databases were searched for randomized placebo-controlled trials evaluating the effect of orally administered collagen on OA symptoms using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale and/or the Visual Analog Scale (VAS). Meta-analysis was conducted using a random-effects model and a generic inverse variance method. Heterogeneity was tested using the I statistic index.
Collagen treatment showed a significant reduction in the score of total WOMAC index (WMD - 8.00; 95% CI - 13.04, - 2.95; p = 0.002). After subgroup analysis of the WOMAC subscores, the collagen supplementation revealed a significant decrease in the stiffness subscore (WMD - 0.41; 95% CI - 0.74, - 0.08; p = 0.01), whereas the pain (WMD - 0.22; 95% CI - 1.58, 1.13; p = 0.75) and functional limitation (WMD - 0.62; 95% CI - 5.77, 4.52; p = 0.81) subscores did not have significant differences. Finally, a significant reduction was found in the VAS score after collagen administration (WMD - 16.57; 95% CI - 26.24, - 6.89; p < 0.001).
The results of this meta-analysis showed that collagen is effective in improving OA symptoms by the decrease of both total WOMAC index and VAS score.
骨关节炎（OA）是导致残疾的最常见原因之一，也是一种普遍的慢性疾病。由于胶原治疗 OA 的效果令人满意，其应用正在不断增加。然而，胶原治疗 OA 的可能有益效果目前仍存在争议。本荟萃分析旨在评估胶原补充剂对 OA 症状的治疗效果。
检索了 PubMed-Medline、Scopus 和 Google Scholar 数据库，以评估口服胶原对 OA 症状的影响，使用 Western Ontario 和 McMaster 大学骨关节炎指数（WOMAC）量表和/或视觉模拟量表（VAS）进行随机安慰剂对照试验。采用随机效应模型和通用逆方差法进行荟萃分析。使用 I 统计量检验异质性。
胶原治疗组的总 WOMAC 指数评分（WMD -8.00；95%CI -13.04，-2.95；p=0.002）显著降低。对 WOMAC 亚量表进行亚组分析后，胶原补充剂显示僵硬亚量表评分显著降低（WMD -0.41；95%CI -0.74，-0.08；p=0.01），而疼痛（WMD -0.22；95%CI -1.58，1.13；p=0.75）和功能限制（WMD -0.62；95%CI -5.77，4.52；p=0.81）亚量表评分无显著差异。最后，发现胶原治疗后 VAS 评分显著降低（WMD -16.57；95%CI -26.24，-6.89；p<0.001）。
本荟萃分析结果表明，胶原通过降低总 WOMAC 指数和 VAS 评分，对改善 OA 症状有效。
